Pfizer, Starboard

Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
What activist hedge fund Starboard wants from Pfizer
Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO Jeff Smith.
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management,
Starboard urges Pfizer board to ‘hold management accountable’, FT reports
Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable
Starboard calls for Pfizer board to ‘hold management accountable’
Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference
Pfizer has “significantly overpaid” for recent acquisitions: Starboard Value
Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance on the pharma giant. Read more here.
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.
A Pfight At Pfizer
There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...
STAT2d
Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions
STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...
FiercePharma3d
Pfizer lays off 75 more workers in North Carolina in wake of late-stage DMD trial fail
Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...
Pfizer Q3 Preview: Why The Stock Is A Buy Ahead Of Earnings
Pfizer's Q3 consensus estimate is likely to be exceeded. Despite the underperformance over the past two months, see why PFE ...
Pfizer, Merck Pneumonia Shots Get Backing for Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
BioPharma Dive3d
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
Why I'm Considering Leaning Heavily Into Pfizer
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
An Activist Makes the Case Against Pfizer. CEO Bourla is in His Sights
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.